Why the study?
Late-onset complications such as endoleaks require lifelong follow-up after EVAR, and clinical guidelines and evidence on management have recently updated.
This review summarizes recent evidence and updated clinical guidelines regarding the management of type 2 endoleaks following endovascular aneurysm repair.
Answers are grounded in this paper and cite their sources.
Offers clinicians updated synthesis for type 2 endoleak management; leaves open need for prospective trials to refine guidelines.
EVAR has been used clinically for almost three decades, and it has been widely applied in clinical practice and has been applied to difficult cases as devices and techniques have evolved. Although the major advantage of EVAR is its lower perioperative mortality, compared with open surgery, late-onset complications such as endoleaks have become major issues, requiring lifelong follow-up after EVAR. The clinical guidelines have been updated, and many systematic reviews/meta-analyses and multi-center registries have been published; surgeons must keep up-to-date regarding these changes. In this review, the author reviews evidence on the recent update of the type 2 endoleak management.
No takes yet. Share an insight, caveat, or question.
Yoshiaki Katada (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: